Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986205 and Nivolumab in Hepatocellular Carcinoma
NCT03695250Phase 2Terminated
- Start
- Oct 2018
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of linrodostat in hepatocellular carcinoma (HCC). Primary endpoints: Adverse Events up to 2 years and Objective Response Rate. Started Oct 2018; status: terminated.
02
Drugs
linrodostat
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03695250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03695250.